Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Restarting DOACs after traumatic intracranial hemorrhage
NCT04891861Phase 3Unknown
- Sponsor
- University of Texas at Austin
- Start
- Jul 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of apixaban in Atrial fibrillation (AFib) and venous thromboembolism (VTE) (2 arms), sponsored by University of Texas at Austin. Primary endpoint: 60-day composite endpoint. Status: unknown.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04891861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891861.